Singling out ovarian cancer

GamaMabs' antibody activates immune cells against AMHR2-positive ovarian tumors

GamaMabs Pharma S.A. is developing a first-in-class mAb that has the potential to treat chemotherapy-resistant subtypes of ovarian cancer by activating phagocytosis in tumor-infiltrating immune cells and tethering them to tumor cells expressing a cancer-specific antigen.

GamaMabs' 3C23K is a humanized mAb against anti-Mullerian hormone receptor type II (AMHR2), a protein that is overexpressed on 50-70% of epithelial ovarian tumors and on nearly 100% of mucinous and granulosa ovarian cancers, which do

Read the full 724 word article

How to gain access

Continue reading with a
two-week free trial.